FDA approves new dosing option for Orfadin (nitisinone) in Hereditary Tyrosinemia Type 1- Swedish Orphan Biovitrum
The FDA has approved Orfadin (nitisinone) 20 mg Capsule, from Swedish Orphan Biovitrum, for the treatment of Hereditary Tyrosinemia Type 1 (HT-1). This is the second time this year Sobi is expanding the Orfadin dosing options for HT-1 patients. Orfadin is indicated for use in combination with dietary restriction of tyrosine and phenylalanine.
Treatment with Orfadin is weight-based. As patients grow, they will need progressively higher doses. Having a higher strength capsule may help minimize the number of capsules needed to achieve treatment levels of adolescent and adult patients.
Earlier this year, Sobi announced the approval of Orfadin Oral Suspension. With the availability of the 20 mg Capsule, physicians can further personalize treatment, whether they are infants or adults. ORFADIN is available in capsules (2 mg, 5 mg, 10 mg, and 20 mg) and oral suspension (4 mg/mL).
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma